Gepon / Studies

Natural fragment · 14 amino acids · 1,818 Da

Gepon studies and research data

PepBank has 12 gepon studies with results. 7 of them gave gepon, with 52 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 52 results and 18 papers. Newer studies from Europe PMC

Results in people

35% of 52 results

Results in animals

40% of 52 results

Results in lab cells

25% of 52 results

From computer models

0% of 52 results

The molecule

Gepon identity

Identifiers, parent molecule, targets and development stage, from curated data.

Gepon is a synthetic tetradecapeptide with the sequence TEKKRRETVEREKE, which matches human ezrin residues 325-338. HEP-1, Hepon and Heponum name this product. The official Russian brand instructions describe local and external use. The register mirror also lists an oral formulation.

Kind: Natural fragment · 14 residues
Identifiers: PubChem CID25078222 (opens in a new tab)CAS174641-44-2
Parent: Fragment of Ezrin · residues 325-338UniProt P15311 residues 325-338 match TEKKRRETVEREKE.
Development: Approved in Russia onlyIMMAPHARMA (manufacturer) / Avexima (registration holder)The Russian brand label names IMMAPHARMA as manufacturer and Avexima as registration holder. NCT04627233 is a phase 1 product trial registration. Its status is UNKNOWN, previously NOT_YET_RECRUITING. Enrollment is estimated at 20. Actual dosing and enrollment are not confirmed. No results are posted. Source (opens in a new tab)

Targets

No molecular target is recorded for this peptide.

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

14 amino acids

H-

TEKKRRETVE

REKE

Parent: Ezrin

No sequence is listed for the parent, so no alignment is shown.UniProt P15311 residues 325-338 match TEKKRRETVEREKE.

Properties

From identity sources

Formula: C₇₄H₁₃₂N₂₆O₂₇
Molecular weight: 1,818 g/mol
Monoisotopic mass: 1,816.9755 Da

PubChem CID 25078222(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 1,818.02 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 1,816.9755 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 9.44; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 0.94; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −2.850; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: 87.24; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 20.7; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 6.90 kcal/mol; Mean solubility value (negated) · Boman 2003; Above 2.48: high protein-binding potential (Boman).
Hydrophobic moment (μH): 0.233; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 9.44Bjellqvist (ExPASy) 8.17IPC peptide 9.72IPC protein 8.58

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 9.44 · Net charge at pH 7.4: 0.94

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	7.00
1	6.99
2	6.94
3	6.43
4	4.07
5	1.60
6	1.06
7	0.98
8	0.80
9	0.24
10	−0.38
11	−1.93
12	−3.54
13	−5.26
14	−5.91

Composition

Hydrophobic7% (1)V
Positive43% (6)K R
Negative36% (5)E
Polar14% (2)T

14 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu0 · 0%

M Met0 · 0%

V Val1 · 7%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys3 · 21%

R Arg3 · 21%

D Asp0 · 0%

E Glu5 · 36%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr2 · 14%

C Cys0 · 0%

G Gly0 · 0%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · P15311

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 25078222(opens in a new tab)

C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.170
μH, best 11-residue window: 0.233
Arrow direction: 24°
Residues: 14

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	T	0°	-0.05
2	E	100°	-0.74
3	K	200°	-1.50
4	K	300°	-1.50
5	R	40°	-2.53
6	R	140°	-2.53
7	E	240°	-0.74
8	T	340°	-0.05
9	V	80°	1.08
10	E	180°	-0.74
11	R	280°	-2.53
12	E	20°	-0.74
13	K	120°	-1.50
14	E	220°	-0.74

Results by area

Gepon results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

12 of 18 studies have results (67%), published 2002 to 2020. Top row: every study. Bottom row: studies with results about Gepon, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies18 in all, 2002 to 2021

Studies with results12 in all, 2002 to 2020

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Gepon studies on infections

24 results · people 13 · animals 5 · lab 6

Top 3 of 24 results

In the combined studies, 10 of 37 patients had HCV reductions between -7 log and -3 log after HEP1.Arzneimittel-Forschung, 2007
In the combined studies, 4 of 37 patients had a -3 log HCV reduction after HEP1.Arzneimittel-Forschung, 2007
In the combined studies, 6 of 37 patients had a -2 log HCV reduction after HEP1.Arzneimittel-Forschung, 2007

Gepon studies on liver

2 results · people 2 · animals 0 · lab 0

2 results

In the first study, the response in 16 of 18 patients included normalization of liver enzymes after HEP1.Arzneimittel-Forschung, 2007
In the second study, the response in 8 of 10 patients included normalization of liver enzymes after HEP1.Arzneimittel-Forschung, 2007

Gepon studies on immune system and inflammation

14 results · people 1 · animals 11 · lab 2

Top 4 of 14 results

In patients with HCV and HIV, the CD4/CD8 ratio improved with HEP1.Arzneimittel-Forschung, 2007
In mice with DSS colitis, GEPON reduced Il1b gene activity in colon tissue.Peptides, 2020
In mice with DSS colitis, GEPON reduced Il6 gene activity in colon tissue.Peptides, 2020
In mice with DSS colitis, GEPON reduced Nos2 gene activity in colon tissue.Peptides, 2020

Gepon studies on stomach and gut

3 results · people 1 · animals 2 · lab 0

3 results

In patients with resistant ulcerative colitis, most (83.3%) improved clinically and on endoscopy after Gepon and overcame resistance to basic anti-inflammatory drugs.Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2005
In mice with DSS colitis, GEPON reduced signs of disease in the large intestine.Peptides, 2020
In mice with DSS colitis, GEPON reduced bloody diarrhoea.Peptides, 2020

Gepon studies on side effects

3 results · people 1 · animals 1 · lab 1

3 results

In patients with HCV and HIV, no adverse reactions or side effects were detected with HEP1.Arzneimittel-Forschung, 2007
In mice, Gepon injected into the brain at 0.01-0.1 micrograms was non-toxic.Voprosy virusologii, 2003
In lab and animal HSV infection studies, Gepon was non-toxic, without separate safety results for each model.Voprosy virusologii, 2003

Gepon studies on survival and serious illness

1 result · people 0 · animals 1 · lab 0

1 result

In mice infected with HSV type 2, Gepon increased average lifespan by 1.9 days.Voprosy virusologii, 2003

Gepon studies on weight and appetite

1 result · people 0 · animals 1 · lab 0

1 result

In mice with DSS colitis, GEPON reduced weight loss.Peptides, 2020

Gepon studies on receptors and cell signals

4 results · people 0 · animals 0 · lab 4

Top 3 of 4 results

In cells, Gepon induced shape and biochemical changes characteristic of differentiated fibroblasts.European journal of pharmacology, 2017
In cells, Gepon activated only ERK-dependent signaling, whereas TGF-β1 activated canonical and non-canonical pathways.European journal of pharmacology, 2017
In cells, Gepon did not change SMAD-dependent signaling in fibroblasts.European journal of pharmacology, 2017

Trials and papers

Gepon trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

1 more mentions it but does not test it. They are not trials of Gepon: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

18 studies match. Retracted studies are left out.

Showing 14 of 18 studiesquery qry_ea38c4e492af908a32a4abad

Studies with results

12 studies

Animal study (in vivo) · mouse · 2020

16 results

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G⁺ granulocytes and Ly6C⁺ monocytes.

Chulkina et al. 2020Peptidescited by 9

PMID 32621844DOI 10.1016/j.peptides.2020.170364PUB-32621844

Full text at the publisher16 results where Gepon was given

Publisher page See results (16)

Not a test of Gepon alone · 2010

1 result

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.

Schildgen et al. 2010Virology journalcited by 6

PMID 20646332PMC2914674DOI 10.1186/1743-422x-7-167PUB-20646332

CC BY1 result where Gepon was a tool, carrier or part of a combination

Download PDF See results (1)

Non-randomized trial · 2007

17 results

Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.

Salamov et al. 2007Arzneimittel-Forschungn = 37cited by 4

PMID 17803064DOI 10.1055/s-0031-1296637PUB-17803064

Full text at the publisher17 results where Gepon was given

Publisher page See results (17)

In vitro (cells) · 2002

3 results

[Ani immunomodulator Hepon inhibits hepatitis C virus replication in human cell cultures in vitro].

Ataullakhanov et al. 2002Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]cited by 1

PMID 12515090PUB-12515090

Full text at the publisher3 results where Gepon was given

Publisher page See results (3)

Not a test of Gepon alone · 2003

2 results

[Hepon, promoter of local immunity in the complex therapy of dysfunctional microflora in bowel disorders].

Parfenov et al. 2003Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterologycited by 1

PMID 14556551PUB-14556551

Full text at the publisher2 results where Gepon was a tool, carrier or part of a combination

Publisher page See results (2)

Animal study (in vivo) · mouse · 2003

6 results

[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].

Barinskiĭ et al. 2003Voprosy virusologiicited by 1

PMID 14598478PUB-14598478

Full text at the publisher6 results where Gepon was given

Publisher page See results (6)

Non-randomized trial · 2005

1 result

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

Malakhova et al. 2005Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterologyn = 36cited by 1

PMID 15991847PUB-15991847

Full text at the publisher1 result where Gepon was given

Publisher page See results (1)

Not a test of Gepon alone · 2017

1 result

[Local immune and oxidative status in exacerbated chronic apical periodontitis].

Konoplya et al. 2017Stomatologiiacited by 1

PMID 28617403DOI 10.17116/stomat201796326-29PUB-28617403

Full text at the publisher1 result where Gepon was a tool, carrier or part of a combination

Publisher page See results (1)

In vitro (cells) · mouse · 2017

6 results

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.

Chulkina et al. 2017European journal of pharmacologycited by 1

PMID 28668507DOI 10.1016/j.ejphar.2017.06.033PUB-28668507

Full text at the publisher4 results where Gepon was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (6)

Not a test of Gepon alone · 2017

3 results

[Disorders in structural-functional properties of erythrocytes in experimental acute destructive pancreatitis of alcohol etiology and their correction].

Konoplja et al. 2017Biomeditsinskaia khimiiacited by 1

PMID 29251614DOI 10.18097/pbmc20176306527PUB-29251614

Full text at the publisher3 results where Gepon was a tool, carrier or part of a combination

Publisher page See results (3)

Animal study (in vivo) · outbred white mice · 2003

5 results

[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus].

Gribencha et al. 2003Voprosy virusologii

PMID 12945207PUB-12945207

Full text at the publisher5 results where Gepon was given

Publisher page See results (5)

Not a test of Gepon alone · 2018

1 result

[The use of immunomodulators, antioxidants and hepatoprotectors for the correction of the liver, erythrocites and the immune system disorders in chronic ethanol intoxication].

Dolgareva et al. 2018Biomeditsinskaia khimiia

PMID 30135284DOI 10.18097/pbmc20186404360PUB-30135284

Rights unknown1 result where Gepon was a tool, carrier or part of a combination

Source link See results (1)

More studies

2 studies

PubMed tag: Review · 2009

Synthetic and natural immunomodulators acting as interferon inducers.

Silin et al. 2009Current pharmaceutical designcited by 27

PMID 19355963DOI 10.2174/138161209787846847PUB-19355963

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2021

Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity.

Holms et al. 2021International journal of molecular sciencescited by 8

PMID 34769119PMC8584018DOI 10.3390/ijms222111688PUB-34769119

CC BY

Download PDF

No result for Gepon (4 studies on this page)

These studies name Gepon but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Randomized Controlled Trial, Clinical Trial · 2004

[Experimental and clinical study of immunomodulators Immunomax and Gepon in complex treatment of acute purulent surgical infection].

Chadaev et al. 2004Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]

PMID 15690909PUB-15690909

Full text at the publisher

Publisher page

PubMed tag: Clinical Trial · 2005

[Administration of the immunomodulator gepon after tonsillectomy].

Starosvetskiĭ et al. 2005Vestnik otorinolaringologii

PMID 16034352PUB-16034352

Full text at the publisher

Publisher page

PubMed tag: Comparative Study · 2006

[Efficacy study of immunomodulator Gepon in treatment of oral membrane diseases in patients with complications in the form of filling material extrusion into mandibular canal].

Sirak et al. 2006Stomatologiia

PMID 16710276PUB-16710276

Full text at the publisher

Publisher page

PubMed tag: none · 2007

Trophic venous ulcers and their relationship with the immune status.

Kirienko et al. 2007Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery

PMID 17679977PUB-17679977

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Gepon studies: 12 papers with results

Page 1 of 1

Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.
Salamov G · Arzneimittel-Forschung · 2007
Non-randomized trial · 17 results
[Use of the Gepon immunomodulator for ulcerative colitis treatment].
Malakhova NS · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · 2005
Non-randomized trial · 1 result
Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.
Chulkina MM · Peptides · 2020
Animal study (in vivo) · mouse · 16 results
[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].
Barinskiĭ IF · Voprosy virusologii · 2003
Animal study (in vivo) · mouse · 6 results
[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus].
Gribencha SV · Voprosy virusologii · 2003
Animal study (in vivo) · outbred white mice · 5 results
Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.
Chulkina M · European journal of pharmacology · 2017
In vitro (cells) · mouse · 6 results
[Ani immunomodulator Hepon inhibits hepatitis C virus replication in human cell cultures in vitro].
Ataullakhanov RI · Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] · 2002
In vitro (cells) · 3 results
[Disorders in structural-functional properties of erythrocytes in experimental acute destructive pancreatitis of alcohol etiology and their correction].
Konoplja AI · Biomeditsinskaia khimiia · 2017
Not a test of Gepon alone · 3 results
[Hepon, promoter of local immunity in the complex therapy of dysfunctional microflora in bowel disorders].
Parfenov AI · Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · 2003
Not a test of Gepon alone · 2 results
Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.
Schildgen V · Virology journal · 2010
Not a test of Gepon alone · 1 result
[Local immune and oxidative status in exacerbated chronic apical periodontitis].
Konoplya AI · Stomatologiia · 2017
Not a test of Gepon alone · 1 result
[The use of immunomodulators, antioxidants and hepatoprotectors for the correction of the liver, erythrocites and the immune system disorders in chronic ethanol intoxication].
Dolgareva SA · Biomeditsinskaia khimiia · 2018
Not a test of Gepon alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Exact-name agency searches did not establish an FDA approval. This is a search limit, not proof of absence. Compounding eligibility remains unverified.	27 Oct 2026	Not recorded
EU	EMA	Exact-name agency searches did not establish central EMA authorisation. EU national authorisations were not established. This is not proof of absence.	27 Oct 2026	Not recorded
Sport	WADA	Status unknown Gepon and its listed aliases are not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
Russia	National register	Approved in Russia The register mirror records P N000015/01. Its EAEU revision dated 2024-12-26 gives expiry 2030-09-26. The main downloaded record does not state an expiry. The mirror lists oral 10 mg and local/external 1 mg and 2 mg formulations. Brand instructions cover local and external use.	27 Oct 2026	pharmcontrol.ru (opens in a new tab)

Safety outcomes

3 safety results for Gepon.

Human evidence· 1

In the HCV/HIV studies, no adverse reactions or side effects were detected during HEP1 therapy.
Non-randomized trialn not reported

Animal evidence· 1

In outbred white mice, intracerebral Gepon at 0.01-0.1 micrograms was non-toxic.
Animal study (in vivo)outbred white mice

Lab evidence· 1

In experimental HSV infection studies, Gepon was non-toxic, without a model-specific safety result.
In vitro (cells)

Doses studied · 5

The doses that these studies used. They are not recommendations.

0.1 and 1 mcg/mouseAnimal
Species
mice
Route
Not reported
Duration
Not reported
Design
Animal study (in vivo)
0.01-0.1 microgramsAnimal
Species
outbred white mice
Route
intracerebral
Duration
Not reported
Design
Animal study (in vivo)
0.1 microgramAnimal
Species
outbred white mice
Route
intramuscular in the virus locus
Duration
Not reported
Design
Animal study (in vivo)
6.25 mcg/ILab
Species
Not reported
Route
Not reported
Duration
Not reported
Design
In vitro (cells)
1 mcg/mLLab
Species
human
Route
Not reported
Duration
Not reported
Design
In vitro (cells)

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
0.1 and 1 mcg/mouse	Animal	mice	Not reported	Not reported	Animal study (in vivo)
0.01-0.1 micrograms	Animal	outbred white mice	intracerebral	Not reported	Animal study (in vivo)
0.1 microgram	Animal	outbred white mice	intramuscular in the virus locus	Not reported	Animal study (in vivo)
6.25 mcg/I	Lab	Not reported	Not reported	Not reported	In vitro (cells)
1 mcg/mL	Lab	human	Not reported	Not reported	In vitro (cells)

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000135
Peptide version: 2
Peptide hash: 7c0ed5d39dabf679…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287291
27 Oct 2026CreatedData version 256685

For developers

curl -s https://pepbank.io/v1/briefs/gepon

Evidence summary for Gepon: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Antiviral activityInfection	Human: 13 results from 1 study: 11 decrease, 2 not reported. Strongest design: Non-randomized trial	Animal: 5 results from 2 studies: 4 increase, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 6 results from 2 studies: 2 increase, 2 decrease, 1 no significant change, 1 not reported. Strongest design: In vitro (cells)	No results	24
Liver fat and liver functionLiver	Human: 2 results from 1 study: 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	2
Adverse eventsWhole body	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells)	No results	3
Gastrointestinal protectionGastrointestinal	Human: 1 result from 1 study: 1 increase. Strongest design: Non-randomized trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	No results	No results	3
Immune responseImmune and inflammation	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	1
Inflammation markersImmune and inflammation	No results	Animal: 11 results from 1 study: 7 decrease, 4 no significant change. Strongest design: Animal study (in vivo)	Lab: 2 results from 1 study: 2 decrease. Strongest design: In vitro (cells)	No results	13
Receptor activity and mechanismSkin and wound	No results	No results	Lab: 4 results from 1 study: 1 increase, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	4
Body weightMetabolic and weight	No results	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	No results	No results	1
MortalityInfection	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Gepon studies and research data

Gepon identity

Targets

Sequence and structure

Sequence

Parent: Ezrin

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

Gepon results by year and outcome

What the studies measured

Gepon studies on infections

Gepon studies on liver

Gepon studies on immune system and inflammation

Gepon studies on stomach and gut

Gepon studies on side effects

Gepon studies on survival and serious illness

Gepon studies on weight and appetite

Gepon studies on receptors and cell signals

Gepon trials

Papers

Studies with results

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.

Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.

[Ani immunomodulator Hepon inhibits hepatitis C virus replication in human cell cultures in vitro].

[Hepon, promoter of local immunity in the complex therapy of dysfunctional microflora in bowel disorders].

[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

[Local immune and oxidative status in exacerbated chronic apical periodontitis].

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.

[Disorders in structural-functional properties of erythrocytes in experimental acute destructive pancreatitis of alcohol etiology and their correction].

[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus].

[The use of immunomodulators, antioxidants and hepatoprotectors for the correction of the liver, erythrocites and the immune system disorders in chronic ethanol intoxication].

More studies

Synthetic and natural immunomodulators acting as interferon inducers.

Ezrin Peptide Therapy from HIV to COVID: Inhibition of Inflammation and Amplification of Adaptive Anti-Viral Immunity.

[Experimental and clinical study of immunomodulators Immunomax and Gepon in complex treatment of acute purulent surgical infection].

[Administration of the immunomodulator gepon after tonsillectomy].

[Efficacy study of immunomodulator Gepon in treatment of oral membrane diseases in patients with complications in the form of filling material extrusion into mandibular canal].

Trophic venous ulcers and their relationship with the immune status.

Newer studies

Gepon studies: 12 papers with results

Regulatory and safety

Human evidence· 1

Animal evidence· 1

Lab evidence· 1

Doses studied · 5

Data and API

Peptide

Latest changes

For developers

Related peptides

Gepon results by year and outcome

Gepon studies on infections

Gepon studies on liver

Gepon studies on immune system and inflammation

Gepon studies on stomach and gut

Gepon studies on side effects

Gepon studies on survival and serious illness

Gepon studies on weight and appetite

Gepon studies on receptors and cell signals

Gepon trials

Papers

Studies with results

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G+ granulocytes and Ly6C+ monocytes.

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case.

Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.

[Ani immunomodulator Hepon inhibits hepatitis C virus replication in human cell cultures in vitro].

[Hepon, promoter of local immunity in the complex therapy of dysfunctional microflora in bowel disorders].

[The antiviral activity of peptide immunomodulator "Gepon" in experimental infections caused by herpes simplex viruses types 1 and 2].

[Use of the Gepon immunomodulator for ulcerative colitis treatment].

[Local immune and oxidative status in exacerbated chronic apical periodontitis].

Synthetic peptide TEKKRRETVEREKE derived from ezrin induces differentiation of NIH/3T3 fibroblasts.

[Disorders in structural-functional properties of erythrocytes in experimental acute destructive pancreatitis of alcohol etiology and their correction].

[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus].

[The use of immunomodulators, antioxidants and hepatoprotectors for the correction of the liver, erythrocites and the immune system disorders in chronic ethanol intoxication].

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G⁺ granulocytes and Ly6C⁺ monocytes.

Pharmaceutical grade synthetic peptide Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu ameliorates DSS-induced murine colitis by reducing the number and pro-inflammatory activity of colon tissue-infiltrating Ly6G⁺ granulocytes and Ly6C⁺ monocytes.